Literature DB >> 12463471

Use of contrast enhanced magnetic resonance imaging to detect spinal inflammation in patients with spondyloarthritides.

M Bollow1, C Enzweiler, M Taupitz, W Golder, B Hamm, J Sieper, J Braun.   

Abstract

Inflammation of spinal structures is a characteristic feature of the spondyloarthritides (SpA). The term SpA covers patients with inflammatory back pain and/or peripheral arthritis who can be further categorized. Ankylosing spondylitis (AS), the prototype of the SpA, the most frequent inflammatory spinal disease in adults, usually starts in the sacroiliac joints. Pathologic spinal changes occurring in AS are spondylitis, spondylodiscitis and inflammation and ankylosis also at other sites in the axial skeleton. In the later stages of AS such changes can be well recognized by spinal x-rays. In the early disease stages it has been more difficult to analyze the exact anatomic localization of spinal inflammation to date, because conventional imaging systems have only a limited capacity to demonstrate such changes early. There is some evidence that magnetic resonance imaging (MRI) with fat saturation and contrast enhanced MRI are useful to visualize early and late inflammatory changes in the sacroiliac joints. In this paper we report that MRI is also useful to localize the site of inflammation to distinct regions of the spine in AS and other SpA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12463471

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

1.  Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems.

Authors:  J Braun; X Baraliakos; W Golder; K-G Hermann; J Listing; J Brandt; M Rudwaleit; S Zuehlsdorf; M Bollow; J Sieper; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2004-04-05       Impact factor: 19.103

2.  Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept.

Authors:  M Rudwaleit; X Baraliakos; J Listing; J Brandt; J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2005-03-18       Impact factor: 19.103

Review 3.  Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis.

Authors:  Rachael Stovall; Irene E van der Horst-Bruinsma; Shao-Hsien Liu; Tamara Rusman; Lianne S Gensler
Journal:  Nat Rev Rheumatol       Date:  2022-09-15       Impact factor: 32.286

4.  Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.

Authors:  M Rudwaleit; J Listing; J Brandt; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2004-03-22       Impact factor: 19.103

5.  Comparison of performance of the Assessment of SpondyloArthritis International Society, the European Spondyloarthropathy Study Group and the modified New York criteria in a cohort of Chinese patients with spondyloarthritis.

Authors:  Ho Yin Chung; Chak Sing Lau; Ka Pik Wu; Woon Sing Wong; Mo Yin MOK
Journal:  Clin Rheumatol       Date:  2011-02-19       Impact factor: 2.980

6.  Whole body MR imaging in ankylosing spondylitis: a descriptive pilot study in patients with suspected early and active confirmed ankylosing spondylitis.

Authors:  Ulrich Weber; Christian W A Pfirrmann; Rudolf O Kissling; Juerg Hodler; Marco Zanetti
Journal:  BMC Musculoskelet Disord       Date:  2007-02-27       Impact factor: 2.362

7.  [Answering epidemiologic rheumatologic questions by cooperation with the large population-based SHIP cohort-findings with relevance for the diagnosis of axial spondyloarthritis (axSpA)].

Authors:  J Braun; A Richter; C Schmidt; X Baraliakos
Journal:  Z Rheumatol       Date:  2021-07-15       Impact factor: 1.372

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.